Cover Image
市場調查報告書

CXC趨化素受體類型4 (Fusin/白血球來源、七跨膜區受體、脂多醣相關蛋白質3、基質細胞來源因子1受體、CD184、CXCR4):開發中產品分析

C-X-C Chemokine Receptor Type 4 - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 363566
出版日期 內容資訊 英文 108 Pages
訂單完成後即時交付
價格
Back to Top
CXC趨化素受體類型4 (Fusin/白血球來源、七跨膜區受體、脂多醣相關蛋白質3、基質細胞來源因子1受體、CD184、CXCR4):開發中產品分析 C-X-C Chemokine Receptor Type 4 - Pipeline Review, H2 2016
出版日期: 2016年10月26日 內容資訊: 英文 108 Pages
簡介

本報告提供全球各國的CXC趨化素受體類型4 (別名Fusin/白血球來源、七跨膜區受體,脂多醣相關蛋白質3,為您概述為以下內容基質細胞來源因子1受體,CD184,CXCR4) 治療藥的開發中產品的開發情形相關分析,產品開發、上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

  • 簡介
    • 分析範圍
  • CXC趨化素受體類型4 (Fusin/白血球來源、七跨膜區受體,脂多醣相關蛋白質3,基質細胞來源因子1受體,CD184,CXCR4)的概要
  • 治療藥的開發情形
    • 臨床實驗的各階段
    • 各治療領域
    • 各症狀
  • 開發中產品的概要
    • 後期階段的產品
    • 初期階段的產品
    • 不明階段的產品
  • 各企業開發中的治療藥
  • 各大學、研究機關開發中的治療藥
  • 治療藥的評估
    • 單劑治療藥/並用治療藥的情況
    • 各作用機制
    • 各投藥法
    • 各分子類型
  • 開發治療藥的企業
    • AdAlta Pty Ltd.
    • Ambrx, Inc.
    • Anchor Therapeutics, Inc.
    • Biokine Therapeutics Ltd.
    • BioLineRx, Ltd.
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • Globavir Biosciences, Inc.
    • GlycoMimetics, Inc.
    • NeED Pharma s.r.l.
    • Pharis Biotec GmbH
    • Polyphor Ltd.
    • Sanofi
    • TaiGen Biotechnology Co., Ltd.
    • Upsher-Smith Laboratories, Inc.
    • X4 Pharmaceuticals, Inc.
  • 藥物簡介
  • 開發暫停的產品
  • 開發中止的產品
  • 值得注意的最新趨勢、新聞稿
  • 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0614TDB

Title: C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Pipeline Review, H2 2016.

Summary

Global Markets Direct's, 'C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Pipeline Review, H2 2016', provides in depth analysis on C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted pipeline therapeutics.

The report provides comprehensive information on the C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4)
  • The report reviews C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
  • List of Tables
  • List of Figures
  • Introduction
  • Global Markets Direct Report Coverage
  • C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) Overview
  • Therapeutics Development
  • C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Products under Development by Stage of Development
  • C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Products under Development by Therapy Area
  • C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Products under Development by Indication
  • C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Pipeline Products Glance
  • Late Stage Products
  • Early Stage Products
  • C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Products under Development by Companies
  • C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Products under Development by Universities/Institutes
  • C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Therapeutics Assessment
  • Assessment by Monotherapy/Combination Products
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Companies Involved in Therapeutics Development
  • AdAlta Pty Ltd.
  • Ambrx, Inc.
  • BioLineRx, Ltd.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Globavir Biosciences, Inc.
  • GlycoMimetics, Inc.
  • Juventas Therapeutics, Inc.
  • Pharis Biotec GmbH
  • Polyphor Ltd.
  • TaiGen Biotechnology Co., Ltd.
  • Upsher-Smith Laboratories, Inc.
  • X4 Pharmaceuticals, Inc.
  • C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Drug Profiles
  • AD-114 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ALB-408 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AM-3114 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • balixafortide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BL-8040 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • burixafor - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GBV-4086 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GMI-1359 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HPH-112 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HPH-196 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HPH-211 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • hz-515H7 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • JVS-100 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LY-2510924 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Monoclonal Antibody Conjugate to Antagonize CXCR4 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Monoclonal Antibody to Antagonize CXCR4 for Breast Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • POL-5551 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Protein to Agonize CXCR4 for Inflammation - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PTX-9908 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Q-122 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Recombinant Protein to Antagonize CXCR4 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Recombinant Proteins to Antagonize CXCR4 for Oncology and Autoimmune Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Synthetic Peptide to Target CXCR4 and SDF-1 for HIV - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ulocuplumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • USL-311 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • X-4P001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • X-4P002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Dormant Projects
  • C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Discontinued Products
  • C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Featured News & Press Releases
  • Oct 14, 2016: AdAlta update on Orphan Drug Designation application for lead drug targeting idiopathic pulmonary fibrosis
  • Oct 05, 2016: BioLineRx Announces Acceptance of BL-8040 Abstracts for Oral and Poster Presentations at 58th American Society of Hematology (ASH) Annual Meeting
  • Sep 27, 2016: X4 Pharmaceuticals Announces Initiation of Phase 1b Study of X4P-001 in Patients with Resectable Stage III and Stage IV Melanoma
  • Sep 20, 2016: BioLineRx Announces Initiation of Phase 2a Trial of BL-8040 in Combination With KEYTRUDA(pembrolizumab) for Treatment of Pancreatic Cancer
  • Sep 12, 2016: AdAlta signs agreement with FujiFilm Diosynth Biotechnologies to begin manufacturing its lead fibrosis drug candidate
  • Sep 08, 2016: BioLineRx Presents Final Results from Phase 2a Trial for Relapsed/Refractory AML at SOHO Conference
  • Sep 06, 2016: GlycoMimetics Initiates Dosing in Phase 1 Clinical Trial of GMI-1359
  • Jun 28, 2016: BioLineRx Announces Regulatory Submissions for Phase 2a Trial of BL-8040 in Combination with KEYTRUDA (pembrolizumab) for Treatment of Pancreatic Cancer
  • May 25, 2016: GlycoMimetics plans to file IND application for GMI-1359
  • May 19, 2016: BioLineRx BL-8040 to be Presented at Upcoming Scientific Conferences
  • May 16, 2016: Upsher-Smith Announces Start Of First In Human Clinical Trial In Oncology With Novel CXCR4 Antagonist USL311
  • May 09, 2016: X4 Pharmaceuticals Announces Initiation of Phase 1/2 Study of X4P-001 in Patients with Advanced Clear Cell Renal Cell Carcinoma
  • Apr 19, 2016: BioLineRx Announces Presentation of Detailed Mechanism of Action Data for Lead Oncology Platform at AACR 2016
  • Apr 19, 2016: X4 Pharmaceuticals Announces Data Presentation for Lead Candidate X4P-001 at AACR Annual Meeting
  • Mar 29, 2016: BioLineRx Reports Successful Top-Line Results in Phase 2 Trial for AML
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by AdAlta Pty Ltd., H2 2016
  • Pipeline by Ambrx, Inc., H2 2016
  • Pipeline by BioLineRx, Ltd., H2 2016
  • Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Pipeline by Eli Lilly and Company, H2 2016
  • Pipeline by Globavir Biosciences, Inc., H2 2016
  • Pipeline by GlycoMimetics, Inc., H2 2016
  • Pipeline by Juventas Therapeutics, Inc., H2 2016
  • Pipeline by Pharis Biotec GmbH, H2 2016
  • Pipeline by Polyphor Ltd., H2 2016
  • Pipeline by TaiGen Biotechnology Co., Ltd., H2 2016
  • Pipeline by Upsher-Smith Laboratories, Inc., H2 2016
  • Pipeline by X4 Pharmaceuticals, Inc., H2 2016
  • Dormant Projects, H2 2016
  • Dormant Projects (Contd..1), H2 2016
  • Dormant Projects (Contd..2), H2 2016
  • Dormant Projects (Contd..3), H2 2016
  • Dormant Projects (Contd..4), H2 2016
  • Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Top 10 Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top